Takeda Pharmaceutical Co., Ltd. (4502)

Tokyo
Currency in JPY
4,365.0
+81.0(+1.89%)
Closed·
4502 Scorecard
Full Analysis
High shareholder yield
High dividend Yield
Fair Value
Day's Range
4,316.04,371.0
52 wk Range
3,852.04,573.0
Key Statistics
Edit
Bid/Ask
4,359.00 / 4,366.00
Prev. Close
4,365
Open
4,328
Day's Range
4,316-4,371
52 wk Range
3,852-4,573
Volume
2.95M
Average Volume (3m)
4.89M
1-Year Change
7.52%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4502 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4,946.6
Upside
+13.32%
Members' Sentiments
Bearish
Bullish
ProTips
Valuation implies a strong free cash flow yield
Show more

Takeda Pharmaceutical Co., Ltd. Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Employees
49281
Market
Japan

Compare 4502 to Peers and Sector

Metrics to compare
4502
Peers
Sector
Relationship
P/E Ratio
64.4x18.0x−0.5x
PEG Ratio
−2.410.130.00
Price/Book
1.0x3.1x2.6x
Price / LTM Sales
1.5x3.3x3.0x
Upside (Analyst Target)
11.2%15.3%52.5%
Fair Value Upside
Unlock21.9%8.7%Unlock

Analyst Ratings

9 Buy
7 Hold
0 Sell
Ratings:
16 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4,946.6
(+13.32% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 68.35%
Dividend Yield
4.58%
Industry Median 2.30%
Annualized payout
196.00
Paid unevenly
5-Years Growth
+1.72%
Growth Streak

Earnings

Latest Release
May 08, 2025
EPS / Forecast
-66.00 / -42.80
Revenue / Forecast
1.0534T / 1.06205T
EPS Revisions
Last 90 days

4502 Income Statement

People Also Watch

3,620.0
8053
+0.78%
2,705.5
5401
+1.22%
220.2
9434
+1.15%
4,350.0
2914
-0.68%

FAQ

What Is the Takeda Pharmaceutical (4502) Stock Price Today?

The Takeda Pharmaceutical stock price today is 4,365.00

What Stock Exchange Does Takeda Pharmaceutical Trade On?

Takeda Pharmaceutical is listed and trades on the Tokyo Stock Exchange stock exchange.

What Is the Stock Symbol for Takeda Pharmaceutical?

The stock symbol for Takeda Pharmaceutical is "4502."

Does Takeda Pharmaceutical Pay Dividends? What’s The Current Dividend Yield?

The Takeda Pharmaceutical dividend yield is 4.49%.

What Is the Takeda Pharmaceutical Market Cap?

As of today, Takeda Pharmaceutical market cap is 6.82T.

What Is Takeda Pharmaceutical's Earnings Per Share (TTM)?

The Takeda Pharmaceutical EPS (TTM) is 68.35.

When Is the Next Takeda Pharmaceutical Earnings Date?

Takeda Pharmaceutical will release its next earnings report on Jul 30, 2025.

From a Technical Analysis Perspective, Is 4502 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Takeda Pharmaceutical Stock Split?

Takeda Pharmaceutical has split 0 times.

How Many Employees Does Takeda Pharmaceutical Have?

Takeda Pharmaceutical has 49281 employees.

What is the current trading status of Takeda Pharmaceutical (4502)?

As of Jun 25, 2025, Takeda Pharmaceutical (4502) is trading at a price of 4,365.00, with a previous close of 4,365.00. The stock has fluctuated within a day range of 4,316.00 to 4,371.00, while its 52-week range spans from 3,852.00 to 4,573.00.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.